987 results about "Rheumatic arteritis" patented technology

The invention discloses preparation and application of bionic cerium-based polyphenol nano-enzyme for treating rheumatoid arthritis, and belongs to the field of medical preparations. The method comprises the following steps: respectively complexing cerium ions and tannic acid or epicatechin gallate to prepare cerium-based polyphenol nano-enzyme, and then preparing the cerium-based polyphenol nano-enzyme wrapped by a macrophage membrane. And loading the cerium-based polyphenol nano-enzyme wrapped by the macrophage membrane into the hydrogel to prepare the hyaluronic acid-based hydrogel. The cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are characterized, it is verified that the cerium-based polyphenol nano-enzyme and the hyaluronic acid-based hydrogel are successfully synthesized, the particle size of CeTA is about 22 nm, the particle size of M-CeTA is increased to 273 nm, the particle size of CeECG is about 95 nm, and the particle size of M-CeECG is increased to 292 nm. In-vitro experiments prove that the M-CeTA and the M-CeECG do not show obvious cytotoxicity when being less than 80 mu g / mL, and have an obvious inhibition effect on expression of cell inflammatory factors on inflammatory cells.

The invention discloses application of citrullinated endolectin-1 polypeptide in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated endolectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE, and the amino acid sequence of the citrullinated endolectin-1 polypeptide is GD- The product is used for detecting the content of the anti-citrullinated endolectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is remarkably different from that of normal healthy people and other common rheumatism immune disease patients easily confused with rheumatoid arthritis in the body of an RA patient. The kit has good sensitivity for common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnostic value for RA diagnosis.

The invention discloses a bacterial polypeptide Gfo and application thereof in preparation of rheumatoid arthritis diagnosis products, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the bacterial polypeptide Gfo is LNSHGFLPETE. A diagnostic product prepared from the bacterial polypeptide Gfo can effectively detect that the level of an anti-bacterial polypeptide Gfo antibody in a biological sample of a rheumatoid arthritis patient is obviously higher than that of healthy people and other rheumatoid immune diseases similar to rheumatoid arthritis. In addition, in CCP antibody and RF negative patients, the increase is still significant. Therefore, the antibacterial polypeptide Gfo antibody is an important biomarker of rheumatoid arthritis, and provides an effective new method for diagnosis of RA, especially diagnosis of serum-negative RA.

The invention relates to an active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation as well as a preparation method and application thereof. Triptolide is coupled with an active oxygen responsive group to synthesize a triptolide derivative; then, the triptolide derivative is coupled with polypeptide, and a polypeptide-reactive oxygen responsive group-triptolide conjugate is obtained; then dissolving the polypeptide-active oxygen responsive group-triptolide conjugate in a solvent, standing, and carrying out self-assembly to obtain a triptolide prodrug nanofiber solution; finally, an immunomodulator is added into the triptolide prodrug nanofiber solution for incubation, and the active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation is obtained. The hydrogel preparation disclosed by the invention can responsively release the medicine triptolide and the immunomodulator at the focus part of rheumatoid arthritis, so that the medicine accumulation of non-target organs is reduced, the safety and effectiveness of treatment are improved, and the progress of diseases is effectively controlled.

The invention relates to the technical field of digital health, in particular to a personalized rehabilitation exercise method for rheumatoid arthritis patients based on a BCW theory, which comprises the following steps: acquiring joint angle change and calculating a pain delay response coefficient, detecting fluctuation of supporting force and stabilizing force to obtain a joint load tolerance value, analyzing respiratory coordination to generate a respiratory coordination index, and performing rehabilitation training on the respiratory coordination index. The method comprises the steps that a joint angle sensor and pain intensity data are analyzed, a BCW capacity factor weight value is generated in a weighted mode, a fuzzy control algorithm is input to conduct hierarchical mapping adjustment on action amplitude frequency and rest intervals, and exercise adaptability feedback data are generated through monitoring completion degree and pain feedback. The exercise intensity is dynamically adjusted in real time through a data model, a personalized rehabilitation scheme is automatically optimized, the problems that subjective feedback is relied on, and physiological changes cannot be responded in time are solved, more accurate exercise amount adjustment is provided, the situation that the joint burden is increased due to improper exercise intensity is avoided, and the rehabilitation process is effectively promoted.

The invention discloses a novel benzofuran component in eupatorium chinense and application of the benzofuran component in anti-inflammatory activity. The obtained compound is separated from an eupatorium chinense extract. The eupatorium chinense root extract is separated by using an extraction method, macroporous adsorption resin impurity removal, Sephadex LH-20 gel column chromatography, high performance liquid chromatography and other methods. According to the present invention, all the separated compounds and the analogues thereof have good inhibition activity on target cyclooxygenase-2 of inflammation-related diseases, and have good inhibition activity on COX-2 enzyme, and the molecular docking experiment results show that the compounds and the target proteins have good binding energy. Therefore, the compound can be used for preparing drugs for treating inflammatory related diseases, or anti-inflammatory and analgesic drugs, or tumor drugs by inhibiting COX-2 enzyme, such as drugs for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, Alzheimer's disease and the like, and related natural lead compounds are provided.

The invention discloses a risk assessment method for rheumatoid arthritis accompanied with cognitive impairment based on big data, and belongs to the field of data feature extraction, and the method specifically comprises the steps: carrying out the unified calling of collected clinical, laboratory and iconography features as an original feature set, and completing the preprocessing through multiple interpolation and Z-score standardization; inputting the original feature set into a self-attention network, and generating interaction feature representation for mining high-order interaction; low-dimensional potential feature vectors are compressed, and combined training is carried out through reconstruction and discriminant loss; inputting the potential feature vectors into an XGBoost model, and screening out a preliminary candidate feature subset; performing global and local importance evaluation on the candidate feature subsets by adopting SHAP, and iteratively rejecting features of which the contribution degrees are lower than a threshold value epsilon until the final feature subset is stable; and respectively inputting the final feature subsets into the simplified ResNet and LightGBM to obtain two groups of risk scores, and then generating a fusion risk score through weighted fusion.

The invention provides a rheumatoid arthritis patient low muscle quality risk prediction method based on an uncertainty perception stacked meta-learning structure, and belongs to the technical field of machine learning. The method comprises the following steps: acquiring a rheumatoid arthritis data set; constructing a base learner set comprising a table Transform class network and a gradient boosting tree class model; splicing the out-of-fold prediction probabilities of all the base learners and the statistics thereof to form a meta-feature matrix; taking the meta feature matrix as input, and constructing and training a meta learner comprising a spectrum normalization multilayer perceptron and a random feature Gaussian process output layer; collecting to-be-detected data, inputting the to-be-detected data into the trained base learner set and the trained meta learner in sequence, and performing temperature scaling and beta-calibration on a prediction result; and taking the calibrated prediction probability as a final prediction result. Through multi-source data fusion, the defects of an existing model in the aspects of practicability, probability reliability and the like are overcome.

The invention discloses a method for predicting periprosthetic infection of an artificial joint after a rheumatoid arthritis operation, and belongs to the technical field of medical treatment, the method can be applied to risk prediction of periprosthetic infection (PJI) of the artificial joint after the rheumatoid arthritis operation, and the method comprises the following steps: carrying out feature selection through a Boruta algorithm; an integrated machine learning algorithm is developed based on a genetic algorithm and an SMOTEENN algorithm in combination with machine learning for risk prediction, so that the accuracy and practicability of PJI risk prediction after joint replacement of a rheumatoid arthritis patient are improved. According to the rheumatoid arthritis artificial joint postoperative periprosthetic infection risk prediction method, a more accurate prediction and personalized treatment scheme can be provided for a doctor, and preoperative management of joint replacement of a rheumatoid arthritis patient is optimized, so that PJI is prevented to the greatest extent, and the joint function and life quality of the patient are improved.

The present application belongs to the technical field of medicine, and particularly relates to the use of tetrahydrojatrorrhizine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating rheumatoid arthritis. Experimental results show that tetrahydrojatrorrhizine can effectively alleviate the foot swelling level of CIA rats, reduce the arthritis score, and inhibit the progression of rheumatoid arthritis. Blood routine analysis shows that the administration of tetrahydrojatrorrhizine reduces the number of immune cells in the blood and weakens the immune level of the body. In addition, the experimental results also show that tetrahydrojatrorrhizine can inhibit synovial hyperplasia and relieve joint damage. Therefore, tetrahydrojatrorrhizine has the prospect of being developed into an oral medicament for treating rheumatoid arthritis, provides more treatment options for clinically treating rheumatoid arthritis, and has important social and economic values.

The present invention relates methods of producing B cell depletion in autoimmune diseases. More specifically, the invention shows the use of CD-19 bispecific targeting molecules to effectively treat autoimmune disorders such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjögren's disease (SjD).

The invention belongs to the field of biological medicines, and particularly relates to application of loganic acid in preparation of a medicine for treating arthritis. Specifically, through experimental research of a collagen-induced arthritis mouse model, the loganin acid is found to be capable of remarkably relieving arthritis symptoms, relieving joint swelling, synovitis and cartilage injury in a dose-dependent manner, and reducing the levels of proinflammatory factors TNF-alpha and IL-6 in plasma. By further combining 16S rRNA sequencing analysis, the loganic acid can remarkably regulate the intestinal microbiota structure of arthritis mice, increase the abundance of Lactobacillus murinus in the intestinal tract and promote the generation of tryptophan metabolite indole-3-acetic acid, so that the effect of resisting rheumatoid arthritis is achieved through an intestinal flora dependent mechanism. Therefore, the invention provides a new application of loganin acid in preparation of a medicine for treating arthritis, and the compound has further research and application values as a potential small molecule medicine.

The invention discloses a prediction model construction method for rheumatoid arthritis accompanied with brain cognitive impairment, and belongs to the technical field of medical assistance, and the method specifically comprises the steps: synchronously collecting multi-source dynamic behavior data when a patient executes standardized joint activity training each time; vector superposition comparison under a three-dimensional coordinate system is carried out on the joint motion trajectory data, and the trajectory offset degree of each motion phase point is calculated; fractal dimension calculation is carried out on the moving path topological structure data, and path complexity is quantized; performing feature matrix construction on the facial micro-expression data, and calculating covariance structure change of an expression parameter matrix; and performing time domain alignment and causal analysis on the spatio-temporal trajectory offset event, the path topology degradation characteristic and the expression parameter variation signal, and when the three types of abnormalities present time coupling in two continuous training periods and meet a preset condition, generating early warning of cognitive impairment.

The invention discloses a rheumatoid arthritis foot orthopedic and warm-keeping device, and relates to the technical field of arthritis foot orthopedic, the rheumatoid arthritis foot orthopedic and warm-keeping device comprises a bottom plate, the bottom plate is fixedly connected with a shell, one side of the bottom of the shell is rotatably connected with an insertion rod, one end of the insertion rod is fixedly connected with a turnover plate, the upper surface of the turnover plate is provided with two connecting blocks, and the two connecting blocks are fixedly connected with the bottom of the shell. And the upper surface of the other end of the bottom plate is fixedly connected with a front plate. According to the rheumatoid arthritis foot orthopedic and warm-keeping device, in the process that a patient lifts the instep upwards for the first time, a limiting rod slides into a short groove from a long groove, a sliding rod extrudes a force storage spring to enable the force storage spring to form downward thrust, the downward thrust formed by extruding the force storage spring by the sliding rod is larger, and therefore the foot orthopedic effect is improved. When the patient lifts the instep upwards for the second time, the downward thrust of the force storage spring helps the patient to lift the instep, the burden of instep muscles of the patient is relieved through the stored force of the force storage spring, and the effect of protecting the joints of the patient is achieved.

Provided herein are compositions and methods for the treatment of an autoimmune or inflammatory disease, such as rheumatoid arthritis. Said compositions comprise a TNFR1 inhibitor. Some embodiments comprise combination therapy featuring the TNFR1 inhibitor with at least one additional anti-inflammatory therapeutic agent.

The present disclosure relates to solid-state forms and corresponding pharmaceutical compositions of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, and methods of treatment, including treatment of rheumatoid arthritis and juvenile idiopathic arthritis using the same. The treatment methods generally comprise administering to a patient (e.g., a pediatric patient) a therapeutically effective amount of upadacitinib as a stable liquid pharmaceutical composition or a solid dosage form, at a dose based on patient body weight.

The present disclosure provides methods of treating rheumatoid arthritis comprising administering a MNK inhibitor.

The invention belongs to the technical field of food and medicine, and relates to application of corn germ concentrated powder in improvement of osteoarthritis. The invention particularly relates to application of corn germ concentrated powder, namely corn antioxidant multienzyme, in preparation of medicines or health-care foods for treating rheumatoid arthritis and osteoporosis. In the corn germ concentrated powder, superoxide dismutase / (U / g) is greater than or equal to 8500, glutathione peroxidase / (U / g) is greater than or equal to 5000, and catalase / (U / g) is greater than or equal to 750. The corn germ concentrated powder can also be prepared by the following method: cleaning corn, germinating, adding water into the germinated corn, grinding and pulping, adding a settling agent into the corn steep liquor, standing, taking supernate, adding part of sodium ascorbate, performing temperature-controlled concentration, adding the rest sodium ascorbate and a stabilizer into the concentrated solution, and uniformly mixing to obtain the corn germ concentrated powder. And drying at controlled temperature, crushing, and mixing with a proper amount of silicon dioxide. The prepared corn germ concentrated powder has the effect of resisting rheumatoid arthritis.

The invention relates to a mesenchymal stem cell immunomodulatory function enhancing technology based on gene editing. The invention relates to the field of biomedical engineering and regenerative medicine, and particularly provides a method for enhancing the immune regulation function of mesenchymal stem cells through a CRISPR-Cas9 gene editing technology, and aims at up-regulating IDO1, IL-10 and other key genes in a targeted manner and remarkably improving the excessive immune response inhibition capability of MSCs. The technology can be used for developing high-efficiency and low-toxicity novel cell drugs for treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.

Disclosed in the present invention are a targeted immunotolerance vaccine, a preparation method therefor, and use thereof. The present invention separately modifies a rheumatoid arthritis-related autoantigen peptide and CTLA4 Ig with DSPE-PEG (DP) to prepare a targeted formulation DP-antigen peptide and a targeted formulation DP-CTLA4, which are then mixed to obtain the vaccine. The vaccine described in the present invention, after intravenous injection, binds to albumin in vivo by means of DSPE, "hitchhiking" on albumin to target and enrich in inflammatory lesions, the spleen, the liver, and other tolerance-inducing sites, inhibiting T cell activation, and inducing anergy and apoptosis of rheumatoid arthritis autoantigen-specific T cells, thereby achieving immunotolerance treatment and prevention of rheumatoid arthritis.

The present invention discloses a rheumatoid arthritis activity grading device based on multimodal data, which mainly includes: an image preprocessing module for converting multiple joint images of a case into image features; an extraction module for extracting all joint image features using TransformerD; an optimized image representation module for obtaining lesion classification predictions of corresponding images and disease grading predictions of the entire image, and calculating a first cross-entropy loss with the corresponding lesion label; an other modality feature extraction module for extracting and enhancing other modality features using MLP; a feature fusion module for interacting and fusing the above-mentioned modality features using TransformerP to obtain disease grading predictions of multimodal data, and calculating a second cross-entropy loss with the true grading label; a loss function optimization module for training a disease activity grading prediction network; a disease grading prediction module for outputting the disease activity of the case from the grading prediction network given the joint images and other modality data of the case.

The invention belongs to the technical field of biomedicine, and particularly relates to application of DHX58 as a diagnostic marker and a therapeutic target of rheumatoid arthritis. Experiments prove that the DXH58 level in rheumatoid arthritis involved parts such as serum and synovial tissues of rheumatoid arthritis patients is remarkably increased, DHX58 and rheumatoid arthritis are positively correlated, and the DHX58 gene or DHX58 protein can be used as a molecular marker for screening or diagnosis or prognosis evaluation of rheumatoid arthritis. Experiments prove that the targeted DHX58 can be used as an effective way for treating rheumatoid arthritis. The application has important meanings for researching the effect of DHX58 in rheumatoid arthritis, understanding the mechanism of RA disease and developing a new treatment strategy.

The present invention discloses the use of 3,4-dihydropsoralen in the preparation of a drug for preventing or treating rheumatoid arthritis. The present invention simulates RA by constructing TNF-a-induced SW982 cells. The results show that 3,4-dihydropsoralen (DP) can downregulate the mRNA expression of inflammatory factors, chemokines, and matrix degrading enzymes through the IL-17 signaling pathway, and affect the IL-17 signaling pathway and the NF-κB signaling pathway to jointly exert an anti-inflammatory effect, thereby effectively improving rheumatoid arthritis. This provides a theoretical basis for the application of 3,4-dihydropsoralen in the clinical treatment of rheumatoid arthritis and opens up new therapeutic drugs and approaches.

The invention relates to a probiotic composition for treating rheumatoid arthritis and application thereof, and relates to the technical field of probiotic compositions.The probiotic composition for treating rheumatoid arthritis is prepared from, by weight, 10-40 parts of lactobacillus johnsonii LBJ 456, 10-30 parts of lactobacillus helveticus HH-LPH17 and 10-30 parts of lactobacillus acidophilus HH-LA26. The bifidobacterium longum subsp. Longum HH-BL18, the bifidobacterium bifidum HH-BB27 and the bifidobacterium longum subsp. Infantis HH-BI27 are prepared from the following raw materials in parts by weight: 10 to 40 parts of bifidobacterium longum subsp. Probiotic strains with specific effects are screened out, the combination proportion of the probiotic strains is optimized, the probiotic composition for treating rheumatoid arthritis is prepared, and a novel safe and effective adjuvant therapy method is provided for treatment of RA.

The invention discloses Witzia ciliaris NCU-33 and application thereof, and belongs to the technical field of microbial medicines. The bacillus coagulans NCU-33 is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number of the bacillus coagulans NCU-33 is CGMCC NO.31779. The strain is separated from a fresh excrement sample of healthy people; the strain is capable of ameliorating and / or preventing rheumatoid arthritis by anti-inflammatory and immunomodulatory effects.

The invention discloses a lindera glauca extract, a preparation method thereof and application of the lindera glauca extract in preparation of drugs for preventing and / or treating rheumatoid arthritis. The research finds that the lindera glauca extract can obviously reverse arthritic rat plantar part swelling and toe bending, relieve ankle joint injury, relieve synovial hyperplasia and inflammatory cell infiltration, inhibit joint fusion, relieve joint gap stenosis, relieve articular surface fusion tendency, increase bone mineral density and bone trabecula number, reduce bone trabecula separation degree and improve joint fusion. The lindera glauca extract can be used for relieving rheumatoid arthritis by protecting the inherent structure of joint tissues and improving inflammation, so that a novel natural medicine choice is provided for preventing and / or treating rheumatoid arthritis.

The invention relates to the technical field of microbiology, in particular to application of Eubacterium rectum to preparation of a preparation for relieving rheumatoid arthritis. It is found for the first time that Eubacterium rectum can improve joint inflammation and bone destruction of mice by adjusting immune tolerance, and the Eubacterium rectum is applied to development of microbial preparations containing Eubacterium rectum so as to improve intestinal flora of rheumatoid arthritis patients, so that the effects of adjusting immunity and relieving rheumatoid arthritis conditions are achieved.

The invention relates to the technical field of health monitoring, in particular to a rheumatoid arthritis patient hand function rehabilitation effect evaluation system in combination with a BCW theory, and the system comprises a behavior analysis module, a capability extraction module, an opportunity evaluation module, an effect analysis module and a stage optimization module. According to the method, the hand track and task records are collected, the execution rate and the duration are extracted and subjected to normalization fitting, a dynamic behavior portrait is constructed, principal component extraction is conducted in combination with the flexion and extension angle and the electromyographic signals, high-weight capacity characteristics are generated, the time difference between triggering and reaction of the device is monitored, the response delay change rate is calculated, and the task time is compared; according to the method, the relation between external stimulation and capability activation is revealed, behavior, capability and response characteristics are fused to construct an effect curved surface, the stability and gradient direction are analyzed, rehabilitation effect three-dimensional quantification and progress trend presentation are achieved, differentiated rehabilitation paths are adapted, and evaluation precision and regulation and control capability are improved.

The invention discloses application of a diagnostic marker in preparation of a rheumatoid arthritis diagnostic product and a diagnostic system, and relates to the technical field of rheumatoid arthritis diagnosis. And the diagnostic marker comprises KMT2B, KMT2C, IFITM3, ECHS1, LYMPH%, MONO%, PDW, Path.CAST, RDW and RDW%. The diagnosis marker provided by the invention has extremely high diagnosis efficiency and has a good application prospect in the field of diagnosis of rheumatoid arthritis.